Gefitinib in treatment of advanced non-small-cell lung cancer as a last treatment option on an Expanded Access Program

被引：0
|
作者：
Zemanova, M [1 ]
Petruzelka, L [1 ]
Honova, H [1 ]
Dvorak, J [1 ]
Safanda, M [1 ]
Mares, P [1 ]
Tomancova, V [1 ]
机构：
[1] Med Univ Gdansk, Dept Radiotherapy & Oncol, Gdansk, Poland
来源：
LUNG CANCER | 2004年 / 45卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S82 / S83
页数：2
相关论文
共 50 条
  • [31] Necitumumab for the treatment of advanced non-small-cell lung cancer
    Diaz-Serrano, Asuncion
    Sanchez-Torre, Ana
    Paz-Ares, Luis
    FUTURE ONCOLOGY, 2019, 15 (07) : 705 - 716
  • [32] Efficacy and safety of gefitinib in chemonaive patients with advanced non-small cell lung cancer treated in an Expanded Access Program
    Govindan, Ramaswamy
    Natale, Ronald
    Wade, James
    Herbst, Roy
    Krebs, Annetta
    Reiling, Richard
    Hensing, Thomas
    Wozniak, Antoinette
    Belani, Chandra P.
    Kelly, Karen
    Ochs, Judith
    LUNG CANCER, 2006, 53 (03) : 331 - 337
  • [33] Gefitinib for patients with advanced non-small cell lung cancer treated on the expanded access program: a single institution experience
    de Souza Cruz, Marcelo Rocha
    Katz, Artur
    Gansl, Rene Claudio
    Tabacoff, Jacques
    Smaletz, Oren
    Simon, Sergio Daniel
    EINSTEIN-SAO PAULO, 2006, 4 (03): : 207 - 212
  • [34] Gefitinib: A new antineoplastic for advanced non-small-cell lung cancer
    Cersosimo, RJ
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2004, 61 (09) : 889 - 898
  • [35] Gefitinib for Chinese patients with advanced non-small-cell lung cancer
    Xiaotong, Z
    Longyun, L
    Xinlin, MU
    LUNG CANCER, 2004, 45 : S79 - S79
  • [36] Gefitinib or Erlotinib in the Treatment of Advanced Non-small Cell Lung Cancer
    Shao, Yu-Yun
    Lin, Chia-Chi
    Yang, Chih-Hsin
    DISCOVERY MEDICINE, 2010, 9 (49) : 538 - 545
  • [37] Efficacy of chemotherapy plus gefitinib treatment in advanced non-small-cell lung cancer patients following acquired resistance to gefitinib
    Song, Zhengbo
    Zhang, Yiping
    MOLECULAR AND CLINICAL ONCOLOGY, 2013, 1 (05) : 875 - 878
  • [38] Compassionate use experience with gefitinib in poor performance (PS) patients with advanced non-small-cell lung cancer (NSCLC) treated in an expanded access program (EAP).
    Zinner, R
    Govindan, R
    Wozniak, AJ
    Wade, JL
    Belani, CP
    Thienelt, CD
    Hensing, TA
    Reiling, RB
    Natale, RB
    Wiznitzer, I
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 636S - 636S
  • [39] Treatment of non-small-cell lung cancer with gefitinib (IRESSA) in a compassionate-use program: The Portuguese experience
    Araujo, A
    Teixeira, M
    Figueiredo, A
    Correia, J
    Melo, M
    Parente, B
    Bernardo, M
    Queiroga, H
    Barata, F
    LUNG CANCER, 2005, 49 : S234 - S234
  • [40] First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer
    Yin Y.-M.
    Geng Y.-T.
    Shao Y.-F.
    Hu X.-L.
    Li W.
    Shu Y.-Q.
    Wang Z.-X.
    Journal of Experimental & Clinical Cancer Research, 29 (1)
12345